BOSTON–(BUSINESS WIRE)– BPGbio, Inc., a number one biology-first, AI-powered, scientific stage biopharma centered on mitochondrial biology and protein homeostasis, in the present day introduced the addition of Dr. Dipanjan Chowdhury, a distinguished most cancers researcher, to its Advisory Board. Along with his intensive experience in early translational analysis and a deep understanding of aggressive stable tumors, Dr. Chowdhury will present helpful steerage to reinforce BPGbio’s preclinical and scientific improvement processes.
This press launch options multimedia. View the total launch right here: https://www.businesswire.com/information/house/20240708275532/en/
Dipanjan Chowdhury, Ph.D. (Photograph: Enterprise Wire)
Dr. Dipanjan Chowdhury, an professional in most cancers remedy, at the moment serves because the Chief of the Division of Radiation and Genome Stability on the Dana-Farber Most cancers Institute, and is a Professor of Radiation Oncology at Harvard Medical College. His groundbreaking analysis on DNA injury restore mechanisms has considerably superior the sphere of most cancers remedy, incomes him quite a few accolades and recognition within the scientific neighborhood. Main The Chowdhury Lab at Dana-Farber, Dr. Chowdhury focuses on understanding the mechanisms of DNA restore and the way these processes affect most cancers improvement and remedy. His lab has recognized key proteins within the DNA injury response and clarified their roles in sustaining genomic stability, which is important for growing novel most cancers therapies to reinforce the effectiveness of current remedies and overcome resistance.
“It’s a privilege to have Dr. Chowdhury be a part of our Scientific Advisory Board,” stated Niven R. Narain, Ph.D., Chairman, President and CEO of BPGbio. “BPGbio’s NAi platform generates an enormous quantity of potential novel targets, together with groundbreaking ones in our E2 protein degraders program that goals to establish methods to focus on pathways lengthy thought-about undruggable. Dr. Chowdhury’s experience in translational most cancers analysis associated to proteins will probably be very helpful in serving to us good our goal validation course of.”
“The staff at BPGbio is on the forefront of advancing medicines on extremely aggressive most cancers phenotypes via their pioneering work in mitochondrial biology and protein homeostasis,” stated Dr. Chowdhury. “I look ahead to contributing to the corporate’s revolutionary efforts and serving to to drive ahead BPGbio’s mission of growing breakthrough therapies for sufferers for unmet wants.”
About BPGbio Inc.
BPGbio is a number one biology-first AI-powered scientific stage biopharma centered on mitochondrial biology and protein homeostasis. The corporate has a deep pipeline of AI-developed therapeutics spanning oncology, uncommon illness and neurology, together with a number of in late-stage scientific trials. BPGbio’s novel strategy is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and worldwide patents; one of many world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and unique entry to probably the most highly effective supercomputer on this planet. With these instruments, BPGbio is redefining how affected person biology could be modeled utilizing bespoke Bayesian AI particularly designed for fixing large-scale biology challenges. Headquartered in larger Boston, the corporate is on the forefront of a brand new period in medication, combining biology, multi-modal information, and AI to rework the best way we perceive, diagnose, and deal with illness. For extra data, go to www.bpgbio.com.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240708275532/en/
Supply: BPGbio, Inc.
Dipanjan Chowdhury, Ph.D. (Photograph: Enterprise Wire)
